Evaluating Erythropoietin as an Indicator for Possible Kidney Injury After Cardiac Surgery
EPO
EPO: A Renal Biomarker After Cardiac Surgery
1 other identifier
observational
80
1 country
1
Brief Summary
The purpose of the study is to evaluate kidney biomarkers and determine if there is a correlation between Erythropoietin (EPO) levels and acute kidney injury after cardiac surgery. An early biomarker for kidney injury may be helpful in identifying, monitoring and managing patients at risk for kidney failure after cardiac surgery. To evaluate Erythropoietin's role as a predictor of poor renal function in the immediate post-bypass period we plan to compare EPO levels to Neutrophil gelatinase-associated lipocalin (NGAL).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2010
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2010
CompletedFirst Submitted
Initial submission to the registry
July 12, 2011
CompletedFirst Posted
Study publicly available on registry
July 13, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2012
CompletedDecember 15, 2016
December 1, 2016
1.3 years
July 12, 2011
December 14, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Renal injury/Failure
18 Hours after surgery
Study Arms (1)
Subjects undergoing cardiac surgery
Interventions
Eligibility Criteria
Cardiac surgery patients.
You may qualify if:
- Cardiac surgery with cardiopulmonary bypass with DHCA
- Normal renal function or renal insufficiency-serum creatinine less than 2.5 mg/dL
- Adult male and female patients 18 years and older
You may not qualify if:
- VADS
- Emergent cases
- Prolonged hypoxemia before, during or after bypass
- End stage renal disease
- Patients receive erythropoietin receptor agonists
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Michigan Hospital
Ann Arbor, Michigan, 48109, United States
Biospecimen
Blood
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yasser El Kouatli, MD
Department of Anesthesiology, University of Michigan
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Lecturer
Study Record Dates
First Submitted
July 12, 2011
First Posted
July 13, 2011
Study Start
November 1, 2010
Primary Completion
March 1, 2012
Study Completion
March 1, 2012
Last Updated
December 15, 2016
Record last verified: 2016-12
Data Sharing
- IPD Sharing
- Will not share